Navigation Links
Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
Date:6/4/2008

Company Expects FDA to Request Additional Safety Study Prior to Approval

LEXINGTON, Mass., June 4 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that based on a recent discussion with the U.S. Food and Drug Administration (FDA) regarding the NDA filing for NEBIDO(R), the Company expects the FDA to formally request that the Company provide additional safety data prior to approving NEBIDO. The Company currently believes that an additional study will be required in order to supply the necessary data. The Company expects to re-file for approval of NEBIDO in approximately 18 months followed by a 6 month FDA review. The Company will finalize the requirements and initiate the study following the receipt of formal communication from the FDA which the Company expects to receive by the original June 27, 2008 PDUFA date.

The Company believes the requirement for additional data relates to a reaction immediately following the injection and is a known rare complication of oil-based depot injections. The reaction is believed to be the result of a small amount of the oily solution immediately entering the vascular system from the injection site and may be due to improper injection technique. The phenomenon is characterized by short-term reactions involving an urge to cough, coughing episodes or a shortness of breath. In rare cases the reaction has been classified as serious or the patient experiences other symptoms such as dizziness, flushing or fainting.

The Company believes that the FDA's safety concern is derived from spontaneous post-marketing adverse event reports of the NEBIDO 1000 mg (4ml) dose. In the Indevus U.S. clinical trials, which included a total of approximately 500 patients, there was a si
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
2. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
3. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
4. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
5. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
6. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
7. MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
9. Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
10. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
11. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... ... with a ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber ... appointments via AdvantaClean’s National Call Center and website since Aug. 17. , The ...
(Date:8/31/2015)... ... 2015 , ... American Family Care (AFC), the nation’s leading ... in Tennessee with the opening of a new urgent care facility at 9203 ... in Tennessee, and 148th in the U.S. overall. , “We’re excited to continue ...
(Date:8/31/2015)... ... August 31, 2015 , ... Kognito , a ... their competencies in managing challenging conversations, announced today that Glenn Albright, Ph.D., the ... of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) Summit taking ...
(Date:8/31/2015)... ... August 31, 2015 , ... In preparation for this November’s National Family ... BEAN™ personal sound amplifier, is offering caregivers “7 Reasons to Care about Hearing Health.” ... coping with a variety of home healthcare challenges, specifically as they relate to caring ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... for physicians and allied health professionals dedicated to using lifestyle as a ... the establishment of the Lifestyle Medicine Lifetime Achievement and Trailblazer Awards, with ...
Breaking Medicine News(10 mins):Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3
... in human cases of bird flu, causing increasing fear of ... in the scientific community to combat this impending and much ... risen since October 5 when scientists from the U.S. Army ... similarities between the bird flu strain in Asia, called H5N1, ...
... flu pandemic has created a stir worldwide with US President ... developers to speed up the process of developing a vaccine ... than 80 countries and international organizations met in Washington on ... officials including those from the World Health Organization (WHO) have ...
... Online Publication, released on the 5th of October, which ... diseases, has a comprehensive report on the threat of ... by Union Health Minister Dr Anbumani Ramadoss, the need ... challenge of chronic diseases in India was highlighted, stating ...
... Though technologic developments bring social and economic benefits ... are difficult to predict and manage. With rapid ... communications, children are increasingly exposed to EMFs at ... childhood leukemia and exposure to extremely low frequency ...
... found a new gene based test for identifying DNA fusion, ... research team is focusing on detection of genes // linked ... called as Acute Lymphoblastic Leukemia (ALL). The researchers took more ... is given by chemotherapy which kills the leukemia cells and ...
... one of life’s most distressing events, bringing in its wake ... reaction to the disease, but could have grave consequences. Because ... have an impact not only on the progression, but also ... in the ordinary course of human life, have been shown ...
Cached Medicine News:Health News:Strategies to prevent the rising tide of the epidemic of chronic diseases 2Health News:Hazards of Electromagnetic Fields for children 2Health News:Depression May Be A Risk Factor For Cancer Initiation 2
(Date:8/31/2015)... N.J. , Aug. 31, 2015  ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today it has completed ... the Data Review Committee (DRC) earlier this year, ... SGX942 is a first-in-class innate defense regulator (IDR) ...
(Date:8/31/2015)... -- Premune and Innovet today ... agreement for Redonyl ® Ultra. The product, which ... dermatology market, is a nutritional supplement based on PEA-um ... dogs and cats. Redonyl ® Ultra is currently ... been received positively in the country by veterinarians and ...
(Date:8/31/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of diseases of the central nervous ... IND submission has passed review by the US Food ... Phase 1 clinical trial in patients with metastatic colon ... to 31 December 2015. Bionomics, CEO & ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... BNVI ), a pharmaceutical company focused on the ... health and cancer, today announced that Dr. Isaac Cohen, O.M.D., ... Cowen and Company 31st Annual Healthcare Conference at 9:30 a.m. ... held at the Boston Marriott Copley Place, in Boston, Massachusetts. ...
... March 7, 2011   PDL BioPharma, Inc. (PDL) ... the first quarter ending March 31, 2011 of approximately $83 ... the first quarter of 2010, an expected 34 percent year-over-year ... million settlement received from UCB Pharma S.A. (UCB) in January ...
Cached Medicine Technology:Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 3PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: